Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00287391 · ClinicalTrials.gov registry record · Phase 4
Sleep Disorders and Gastroesophageal Reflux Disease (GERD)
A Phase 4 study, sponsored by University of North Carolina.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT00287391 is a Phase 4 study that has completed, run by University of North Carolina. The registered enrollment target is 20 participants.
The verdict
NCT00287391, a Phase 4 study, has completed, sponsored by University of North Carolina.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study will investigate Gastroesophageal Reflux Disease (GERD)as a cause of sleep disturbance. Patients with GERD may experience all or some of the following symptoms: stomach acid or partially digested food re-entering the esophagus (which is sometimes referred to as heartburn or regurgitation) and belching. Even very small, unnoticeable amounts of rising stomach acid may cause patients to wake up during the night. This study will also investigate the effect of Rabeprazole, (brand name Aciphex) on patients with known insomnia. Rabeprazole is an FDA approved medication already marketed for the treatment of GERD.
Interventions
- DRUG Rabeprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2004-09 |
| Est. Completion | 2006-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00287391
The ClinicalTrials.gov registry entry for NCT00287391 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rabeprazole is the first listed.
NCT00287391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00287391 about?
NCT00287391 is a clinical study titled "Sleep Disorders and Gastroesophageal Reflux Disease (GERD)". This study will investigate Gastroesophageal Reflux Disease (GERD)as a cause of sleep disturbance. Patients with GERD may experience all or some of the following symptoms: stomach acid or partially digested food re-entering the esophagus (which is sometimes referred to as heartburn or regurgitation)...
What is the current status of trial NCT00287391?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2004-09. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00287391?
The interventions under investigation include: Rabeprazole (DRUG).
Who is sponsoring clinical trial NCT00287391?
This trial is sponsored by University of North Carolina, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.